Dosage: The recommended dose of EVENITY is 210 mg administered subcutaneously. Administer EVENITY once every month for 12 doses.
Patients should be adequately supplemented with calcium and vitamin D [see Contraindications, Precautions, and Pharmacology: Pharmacodynamics: Clinical Data under Actions].
If the EVENITY dose is missed, administer as soon as it can be rescheduled. Thereafter, EVENITY can be scheduled every month from the date of the last dose.
After completing EVENITY therapy, consider transition to an antiresorptive osteoporosis therapy [see Pharmacology: Pharmacodynamics: Clinical Data under Actions]. Treatment should be initiated and supervised by specialist physicians experienced in the management of osteoporosis. After initial training in proper subcutaneous injection technique, an individual may self-inject EVENITY if a physician determines that is appropriate and with medical follow-up as necessary.
The efficacy and safety of treatment with EVENITY for longer than 12 months has not been established.
Method of Administration: Subcutaneous use. Administration should be performed by an individual who has been trained to administer the product.
To administer the 210 mg dose, give 2 subcutaneous injections of EVENITY.
For detailed instructions on storage, handling, and administration, follow the directions provided in the Special Precautions for Disposal and Other Handling under Cautions for Usage.
Important Administration Instructions: Visually inspect EVENITY for particles and discolouration prior to administration. EVENITY is a clear to opalescent, colourless to light yellow solution. Do not use if the solution is cloudy or discoloured or contains particles.
Administer EVENITY in the abdomen, thigh, or upper arm subcutaneously. If patient wants to use the same injection site, make sure it is not the same spot on the injection site patient used for a previous injection. Do not inject into areas where the skin is tender, bruised, red, or hard.